奥希替尼耐药的非小细胞肺癌患者在无TKI间隔期后吉非替尼再敏感：危机时刻的一线希望？

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-06-10 DOI:10.1016/j.cllc.2024.06.003

引用次数: 0

摘要

-在奥希替尼耐药后，一些患者对表皮生长因子受体阻断仍然敏感。-在无TKI间隔期后，重新挑战吉非替尼似乎有效。-液体活检可追踪表皮生长因子受体突变的NSCLC的克隆演变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

•
After osimertinib resistance some patients are still sensitive to EGFR blockage.
•
Gefitinib rechallenge seems effective after a TKI-free interval.
•
Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.
•
Detection of EGFR mutations on ctDNA can identify patients for this strategy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.